Junshi Biosciences Announces Approval of Supplemental New Drug Application by NMPA for Toripalimab in Combination with Cisplatin and Gemcitabine as First-Line Treatment for Patients with Locally Recurrent or Metastatic Nasopharyngeal Carcinoma

Amy Giles
Increasing Engagement

David Linetsky
Point-of-Care Marketing

Pat Purcell
Meeting Engagement

Matt Turner
Patient Affordability

Suma Ramadas, PhD
Medical Affairs

Stacey Gandler
Brand Nourishment

Paul Theisen
Patient Acquisition

Bud Bilanich
Success Coach

Brenda Snow
Authentic Patient Voice

Liz Kane
Impactful Strategy

Frank Burrell
Scientific Storytelling

Joey Cohen
Medication Adherence

Daniel Sontupe
Market Access

Matthew Durham
Omnidynamic Marketing